We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 0.42% | 35.65 | 35.40 | 35.90 | 36.50 | 34.05 | 36.50 | 425,707 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.25 | 106.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/12/2022 09:01 | BLUE START.....persistant buying at these levels......60p by New Year?This is our 12th CONSECUTIVE BLUE DAY.Nice. | broomrigg | |
13/12/2022 20:53 | Interesting bunch of new recruits at Futura. Take a look on LinkedIn, many ex senior GSK folks being brought in by Uncle Ken and JC. I hope they have the cash-flow to prop it up. | suresure | |
13/12/2022 19:03 | The ramper has proven himself the Med3000 tests were deficient as a lot of men with ED just spontaneously recover and need no further treatment. Especially starting at a baseline for the study of 62% needing no treatment to start with! LOL petroc8 Dec '22 - 18:26 - 14487 of 14511 Most common reasons for the discontinuation ‘spontaneous recovery of erectile function without further treatment’ It is known that uncontrolled trials produce higher estimates of the mean effect than those obtained in a controlled trial, since by not having a control group acting as a reference, they can induce erroneous impressions about the results of the investigated drug. As they can generate a certain bias, the results of uncontrolled trials are considered less valid than those of controlled trials. Uncontrolled Trials This design incorporates no control arm. This design is usually utilized to determine pharmacokinetic properties of a new drug (Phase 1 trials). Uncontrolled trials are known to produce greater mean effect estimates than a controlled trial, thereby inflating the expectations from the intervention. There is a threat of inherent bias and results are considered less valid than RCT. Another issue is use of this design in spontaneously resolving maladies that might again overstate the effect | lbo | |
13/12/2022 18:55 | So no attempt by the stock basher to explain why MED3000 doesn't work, even though over 60% of men who have trialled it said it did work. Are they all 'proven liars' too, LiarBO? | petroc | |
13/12/2022 18:48 | So no attempt to explain how a company can expect to enforce a patent on something that they openly admit was already well described in research literature. ‘The Company has conducted initial literature and in vitro based research that has shown the cooling from the evaporation of these specific combinations of solvents’ There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial products A smooth gel intended for alcohol soluble actives. Provides cooling effect upon application while leaving minimal residue The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results. And the brokers too have admitted Dermasys vehicle gel just gave similar results to the Voltarol vehicle gel! ˜TPR100 gave similar results to the gold standard, Voltarol 2% gel’ | lbo | |
13/12/2022 18:04 | Huge rug pull incoming here, a cash guzzling dog of a company... Good luck commercialising a gel placebo with minimal marketing spend! PSML | truant2tb1 | |
13/12/2022 16:53 | ROFLMAO What did the share price get to in March 2021 again after the pump and dump before the last fundraising at 47p!? Those that sold out then at 70p and over are indeed ROFLTAO The real question is why don’t Lombard exercise their warrants and cross the 30% and offer to buy the whole company for 40p!? Especially when brokers are saying it’s supposedly cheap and worth 3x that based on certain assumptions! LOL Lombard Odier will receive a total of 10,937,500 warrants to subscribe for further new Ordinary Shares at a price of 40 pence per share, exercisable until the fifth anniversary of their issue, in respect of its participation in the Subscription. | lbo | |
13/12/2022 16:32 | The more LiarBO says 'ROFLMAO' the more you know he's flapping! It happens every time the share price rises, makes him look really stupid. He thinks it makes him look cool and not bothered, but it's like a nervous person yawning! How's the stock bashing going anyway, LiarBO? Do you think you're winning your crusade? Doesn't look much like it! Just think, 5 years wasted bashing this stock when you could have been doing something useful with your life (aside from testing all those gels and lubes on yourself). And yet the share price still goes up and up! | petroc | |
13/12/2022 15:42 | Deja Vu! Six years later and the ‘very exciting times ahead’ are still ‘we believe’, ‘think’ and’ ‘hope’ are still ahead! LOL But lets not mention how that ‘big group’ distributor has vanished off the face of the planet. Just like the original Futura FAQS did! Surely it will be different this this with Leslie from his flat and Eroxon Limited! ROFMLAO mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141 Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he says mikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141 Company is massively over valued if you go by 'concrete' results ! mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141 I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections. I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the shares Unfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 ! mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591 "A couple of decent deals and will be back off to the races." Do you have any idea of how long shareholders have been using these words mikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591 As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated. All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day! mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713 why should it be any different this time when you've still got the same useless lot running the show mikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641 I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-life And where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remuneration I just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick | lbo | |
13/12/2022 13:42 | Thanks for posting that link SOS100.......a very upbeat interview on Proactive with James Barder, Chief Exec. of Futura. Enjoy....... :-) | broomrigg | |
13/12/2022 12:43 | Petroc I wouldnt waste your time that loser has been posting lies and nonsense 7 days a wee across multiple boards for the last few years!!! Everything he has said is either lies or has been totally wrong The more positive the news the more he poats Facts are Eroxon is about to launch across Europe and the UK Eroxon will launch into the middle east next year The first and most important stage of the De Nova FDA requirements have been accepted They are in detailed discussions with multiple US co's re a commercial deal for the USA. USA launch likely H2 next year Market size is many billion and Futura should easily be able to grab a decent slice of that All in all a revolution is taking place for ED treatments and Futura is in the forefront. | j777j | |
13/12/2022 12:36 | Liberum upped price target to 121p ?!?! | j777j |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions